降钙素原
血液灌流
医学
感染性休克
体外
败血症
多粘菌素B
重症监护室
内科学
胃肠病学
外科
血液透析
抗生素
微生物学
生物
作者
Antonella Cotoia,Valeria Parisano,Paola Sara Mariotti,Vincenzo Lizzi,Giuseppe Stefano Netti,Elena Ranieri,Francesco Forfori,Gilda Cinnella
摘要
Introduction Comparison of the marker kinetics procalcitonin, presepsin and endotoxin during extracorporeal hemoperfusion with polymyxin B adsorbing cartridge (PMX-HA) have never been described in abdominal sepsis. We aim to compare the trend of three biomarkers in septic post-surgical abdominal patients in Intensive care Unit (ICU) treated with PMX-HA and their prognostic value. Methods Ninety abdominal postsurgical patients were enrolled into different groups according to the evidence of postoperative sepsis or not. Non-septic patients admitted in the surgical ward were included in C group (control group). ICU septic shock patients with endotoxin levels <0.6 EAA receiving conventional therapy were addressed in S group and those with endotoxin levels ≥0.6 EAA receiving treatment with PMX-HA, besides conventional therapy, were included in SPB group. Presepsin, procalcitonin, endotoxin and other clinical data were recorded at 24h (T0), 72h (T1) and 7 days (T2) after surgery. Clinical follow-up was performed on day 30. Results SPB group showed reduced levels of the three biomarkers on T2 vs T0 (P<0.001); presepsin, procalcitonin and endotoxin levels decreased respectively of 25%, 11% and 2% on T1 vs T0, and of 40%, 41%, 26% on T2 vs T0. All patients in C group, 73% of patients in SPB group vs 37% of patients in S group survived at follow-up. Moreover, procalcitonin had the highest predictive value for mortality at 30 days, followed by presepsin. Conclusion The present study showed the reliability of presepsin in monitoring PMX-HA treatment in septic shock patients. Procalcitonin showed better predicting power for the mortality risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI